Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/108
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDe Boer, Richarden
dc.contributor.otherChan, Arleneen
dc.contributor.otherSu, Charlesen
dc.contributor.otherGajdatsy, Adamen
dc.date2013-05en
dc.date.accessioned2014-11-11T00:16:39Zen
dc.date.available2014-11-11T00:16:39Zen
dc.date.issued2013-06en
dc.identifier.citationJ Clin Oncol. 2013 Jun 10;31(17):2123-7.en
dc.identifier.issn1527-7755en
dc.identifier.urihttp://hdl.handle.net/11434/108en
dc.description.abstractPURPOSE: To define the incidence and impact of tearing in patients receiving adjuvant docetaxel-based chemotherapy and assess for lacrimal duct obstruction (LDO) as a causative factor. PATIENTS AND METHODS: Consecutive patients with early breast cancer recommended for docetaxel-based chemotherapy with no prior ocular symptoms were included. Before and after completion of chemotherapy, patients underwent lacrimal drainage evaluation by computed tomographic dacrocystography (CT-DCG) and ophthalmic assessment. Eye symptoms were assessed at baseline, during, and after completion of chemotherapy.en
dc.subjectOncologyen
dc.subjectBreast Canceren
dc.subjectBreast Neoplasmsen
dc.subjectDrug Therapy-docetaxelen
dc.subjectChemotherapyen
dc.subjectAdjuvants, Pharmaceuticen
dc.subjectExcessive Tearingen
dc.titlePrevalence of excessive tearing in women with early breast cancer receiving adjuvant Docetaxel-based chemotherapy.en
dc.typeJournal Articleen
dc.typeTexten
dc.identifier.doidoi: 10.1200/JCO.2012.45.6574.en
dc.identifier.journaltitleJournal of Clinical Oncology.en
dc.description.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/23650421en
dc.description.affiliatesCurtin University and Mount Hospital, Australia.en
dc.description.affiliatesMedical Oncology, Epworth Hospital, Australia.en
dc.type.studyortrialObservational prospective study.en
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.